Differential expression of potassium ion channels in human renal cell carcinoma.
OBJECTIVE
Ether-a-go-go (EAG) or EAG-related (ERG) voltage-gated potassium ion channels are involved in tumor generation and progression. Their over- and/or misexpression has been demonstrated in various tumors, and inhibition of these channels has suppressed proliferation of various cancer cells. We investigate and compare the pattern of expression of EAG and human ERG (HERG) channels in renal cell carcinoma and "normal" renal tissue.


METHODS
Tissue samples, obtained at the time of radical nephrectomy from the tumor-bearing areas, and uninvolved renal tissue were preserved in 4% paraformaldehyde and cryosectioned at 20 mum. Immunohistochemical and Western blot analysis was performed on the tumor and uninvolved kidney parenchyma by incubating with polyclonal anti-HERG 1b (Alomone Lab, Israel), anti-EAG1, and anti-EAG2. Pattern of expression of EAG/HERG channels in normal renal tissue and carcinoma were noted and compared.


RESULTS
The study was performed on 16 radical and four partial nephrectomy specimens (n = 20). All tumors in the cohort were clear cell renal carcinoma. Normal renal tissue was found to exhibit heterogeneous cytoplasmic positivity for EAG1 and focal HERG immunoreactivity (IR) in the proximal (PCT) and distal convoluted tubules (DCT). EAG2 IR was absent in the normal renal tissue. Clear cell RCC demonstrated a loss of HERG expression while diffuse overexpression of EAG1 and EAG2 was noted. Western blot analysis corroborated the immunohistochemical observations.


CONCLUSIONS
In our study both EAG1 and EAG2 potassium channels were overexpressed in clear cell renal cancer. In contrast to other adenocarcinomas, there is loss of HERG expression in clear cell RCC, which may possibly explain its chemoresistance. These ion channels may provide a potential for targeted therapy.
Wadhwa
Surbhi
S
Department of Anatomy, All India Institute of Medical Sciences, New Delhi, India.
Wadhwa
Pankaj
P
Dinda
Amit K
AK
Gupta
Narmada P
NP
D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D016022:Case-Control Studies; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels / Q000378:metabolism*; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009392:Nephrectomy
D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; C496884:KCNH1 protein, human; C000606913:KCNH2 protein, human; C092509:KCNH6 protein, human
Br J Cancer. 2000 Dec;83(12):1722-9
11104572
EMBO J. 1999 Oct 15;18(20):5540-7
10523298
FEBS Lett. 2002 Jul 31;524(1-3):204-10
12135768
Leukemia. 2002 Sep;16(9):1791-8
12200695
Oncol Rep. 2002 Sep-Oct;9(5):961-4
12168055
J Biol Chem. 2002 Apr 19;277(16):13673-81
11834728
Cancer Res. 2002 Sep 1;62(17):4843-8
12208728
J Membr Biol. 2002 Jul 15;188(2):137-49
12172639
Am J Physiol Renal Physiol. 2001 May;280(5):F739-47
11292615
J Physiol. 1998 Apr 1;508 ( Pt 1):49-56
9490815
J Membr Biol. 1996 Nov;154(2):91-107
8929284
Cancer Res. 2004 Oct 1;64(19):6996-7001
15466192
Cancer Res. 1998 Feb 15;58(4):815-22
9485040
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10036-40
8234253
Mol Cancer. 2006 Oct 05;5:41
17022810
Nature. 2002 Sep 5;419(6902):35-42
12214225
Cancer Lett. 2002 Dec 1;186(1):99-105
12183081
Cancer Chemother Pharmacol. 2005 Aug;56(2):212-20
15812674